For the quarter ending 2026-03-31, ZNTL has $253,066K in assets. $70,386K in debts. $31,930K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Marketable equity securities | - | 0 | 2,406 | 16,791 |
| Cash and cash equivalents | 31,930 | 35,995 | 39,072 | 37,599 |
| Marketable debt securities, available-for-sale | 179,828 | 209,898 | 239,219 | 249,041 |
| Contracts receivable | - | 0 | 0 | 0 |
| Prepaid expenses and other current assets | 6,338 | 7,298 | 7,605 | 8,165 |
| Total current assets | 218,096 | 253,191 | 288,302 | 311,596 |
| Property and equipment, net | 2,653 | 2,770 | 2,927 | 3,087 |
| Operating leaseright-of-useassets | 25,595 | 26,271 | 30,188 | 31,175 |
| Prepaid expenses and other assets | 4,095 | 4,108 | 3,206 | 3,222 |
| Restricted cash | 2,627 | 2,627 | 2,627 | 2,627 |
| Total assets | 253,066 | 288,967 | 327,250 | 351,707 |
| Accounts payable | 7,378 | 7,208 | 7,031 | 3,719 |
| Accrued expenses | 27,858 | 29,351 | 30,137 | 35,303 |
| Total current liabilities | 35,236 | 36,559 | 37,168 | 39,022 |
| Long-term lease liability | 34,650 | 35,704 | 36,708 | 37,690 |
| Other long-term liabilities | 500 | 500 | 500 | 500 |
| Total liabilities | 70,386 | 72,763 | 74,376 | 77,212 |
| Common stock, 0.001 par value 250,000,000 shares authorized 71,156,113 and 69,085,980 shares issued and outstanding at march31, 2026 and december31, 2025, respectively | 71 | 69 | 72 | 72 |
| Additional paid-in capital | 1,409,466 | 1,407,394 | 1,408,855 | 1,403,912 |
| Accumulated other comprehensive (loss) income | -50 | 196 | 186 | 59 |
| Accumulated deficit | -1,226,807 | -1,191,455 | -1,156,239 | -1,129,548 |
| Total stockholders equity | 182,680 | 216,204 | 252,874 | 274,495 |
| Total liabilities and stockholders equity | 253,066 | 288,967 | 327,250 | 351,707 |
Zentalis Pharmaceuticals, Inc. (ZNTL)
Zentalis Pharmaceuticals, Inc. (ZNTL)